Eloxx Pharmaceuticals Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
ELOX
- Investments
-
2
- Share Price
-
$13.00
- (As of Thursday Closing)
Eloxx Pharmaceuticals General Information
Description
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Contact Information
Website
www.eloxxpharma.comCorporate Office
- 10 Court Street
- PO Box 274
- Arlington, MA 02476
- United States
Corporate Office
- 10 Court Street
- PO Box 274
- Arlington, MA 02476
- United States
Eloxx Pharmaceuticals Stock Performance
As of 12-Nov-2026, Eloxx Pharmaceuticals’s stock price is $13.00. Its current market cap is $52M with 4.04M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.00 | $13.01 | $52M | 4.04M | 30.9K | $3.52 |
Eloxx Pharmaceuticals Financials Summary
As of 30-Jun-2026, Eloxx Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 40 | 983 | 4,755 | |
| Revenue | 0 | 0 | 6,359 | 0 |
| EBITDA | (10,446) | (4,979) | (1,862) | (15,346) |
| Net Income | (10,651) | (5,995) | (3,143) | (17,054) |
| Total Assets | 63,388 | 5,270 | 2,976 | 1,712 |
| Total Debt | 0 | 1,000 | 6,520 | 3,966 |
Eloxx Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eloxx Pharmaceuticals Comparisons
Industry
Financing
Details
Eloxx Pharmaceuticals Competitors (67)
One of Eloxx Pharmaceuticals’s 67 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Galectin Therapeutics | Corporation | Norcross, GA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Regenerx | Formerly VC-backed | Rockville, MD | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Eloxx Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Eloxx Pharmaceuticals Patents
Eloxx Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021061873-A1 | Methods, compositions, and kits for treating polycystic kidney disease | Inactive | 23-Sep-2019 | ||
| AU-2019387385-A1 | Methods, compositions, and kits for treating ocular diseases | Inactive | 29-Nov-2018 | ||
| AU-2019387385-A2 | Methods, compositions, and kits for treating ocular diseases | Inactive | 29-Nov-2018 | ||
| CA-3121498-A1 | Methods, compositions, and kits for treating ocular diseases | Pending | 29-Nov-2018 | ||
| EP-3886864-A1 | Methods, compositions, and kits for treating ocular diseases | Inactive | 29-Nov-2018 | A61K31/7036 |
Eloxx Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Eloxx Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Eloxx Pharmaceuticals Acquisitions (2)
Eloxx Pharmaceuticals’s most recent deal was a Merger/Acquisition with Zikani Therapeutics for . The deal was made on 01-Apr-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zikani Therapeutics | 01-Apr-2021 | Merger/Acquisition | Biotechnology | ||
| Sevion Therapeutics | 19-Dec-2017 | Merger/Acquisition | Drug Discovery |
Eloxx Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Eloxx Pharmaceuticals FAQs
-
When was Eloxx Pharmaceuticals founded?
Eloxx Pharmaceuticals was founded in 2013.
-
Where is Eloxx Pharmaceuticals headquartered?
Eloxx Pharmaceuticals is headquartered in Arlington, MA.
-
What is the size of Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals has 7 total employees.
-
What industry is Eloxx Pharmaceuticals in?
Eloxx Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Eloxx Pharmaceuticals a private or public company?
Eloxx Pharmaceuticals is a Public company.
-
What is Eloxx Pharmaceuticals’s stock symbol?
The ticker symbol for Eloxx Pharmaceuticals is ELOX.
-
What is the current stock price of Eloxx Pharmaceuticals?
As of 12-Nov-2026 the stock price of Eloxx Pharmaceuticals is $13.00.
-
What is the current market cap of Eloxx Pharmaceuticals?
The current market capitalization of Eloxx Pharmaceuticals is $52M.
-
Who are Eloxx Pharmaceuticals’s competitors?
Voyager Therapeutics, Galectin Therapeutics, Dicerna Pharmaceuticals, Regenerx, and CRISPR Therapeutics are some of the 67 competitors of Eloxx Pharmaceuticals.
-
What is Eloxx Pharmaceuticals’s annual earnings per share (EPS)?
Eloxx Pharmaceuticals’s EPS for 12 months was $3.52.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
